(Q33224408)

English

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

interferon alfa

1 reference

based on heuristic

inferred from title

Alexander Eggermont

1

object named as

Alexander M M Eggermont

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

2

object named as

Stefan Suciu

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Ulrich Keilholz

14

object named as

Ulrich Keilholz

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Włodzimierz Ruka

4

object named as

Wlodzimierz Ruka

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

author name string

Rona MacKie

3

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Alessandro Testori

5

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Wim Kruit

6

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Cornelis J A Punt

7

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Michelle Delauney

8

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

François Sales

9

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Gerard Groenewegen

10

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Dirk J Ruiter

11

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Izabella Jagiello

12

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Konstantin Stoitchkov

13

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Danielle Lienard

15

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

EORTC Melanoma Group

16

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

366

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

9492

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1189-1196

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The role interferon-alpha in malignant melanoma remains to be defined

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967482-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(05)67482-X

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33224408&oldid=1958010381"